August 22, 2025

Supplementary Methods from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase 1b/2 study explores TP-0903 and decitabine, targeting mutant TP53 and complex karyotype in patients aged 60+ with acute myeloid leukemia.

TP-0903 and decitabine showed potential in treating acute myeloid leukemia with mutant TP53.
The study focuses on patients aged 60 and older, indicating a need for effective treatment in older populations.
This phase 1b/2 study employs combined therapies, exploring their effects on complex karyotype cases.
Findings may support new treatment strategies for acute myeloid leukemia in older patients with challenging genetics.

Eisenmann et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 1b/2 study explores TP-0903 and decitabine, targeting mutant TP53 and complex karyotype in patients aged 60+ with acute myeloid leukemia.